文献速递免疫规划卫生政策与健康促进

初始疫苗接种年期间接种疫苗预防COVID-19疾病的经济学评价

The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
PubMed 文献 · Vaccine · 2025-01-21

本研究利用模拟模型评估2021年初始接种年期间美国≥18岁成人接种COVID-19疫苗相比不接种的成本效果,按年龄和并发症风险分层,采用2021年3种疫苗产品的汇总接种策略,从医疗保健和社会视角分析。结果显示社会视角下所有年龄和风险组接种均节省成本并增加质量调整生命年;医疗保健视角下18-39岁需净投入,ICER为8400至15000美元/QALY。结论认为2021年疫苗接种计划从经济角度具有吸引力。

要点

  • 社会视角下,所有成人年龄和风险组接种均节省成本并增加QALY。
  • 医疗保健视角下,18-39岁组需净投入,ICER为8400至15000美元/QALY。
  • 疫苗激励计划场景ICER多低于100000美元/QALY,500美元工人奖金场景为22000至134000美元/QALY。

核心结论

  • 2021年疫苗接种计划的投资从经济角度具有吸引力,即使采用非常保守的分析方法。
  • 美国未来疫苗接种计划成本结构不同,应进行评估以确保COVID-19疫苗接种的持续价值。

研究设计与样本

  • 使用模拟模型,预测美国≥18岁成人假设队列的结果,按年龄和并发症风险状态分层。
  • 比较接种疫苗与不接种,背景为推荐的伴随预防策略(如戴口罩、保持社交距离)。
  • 接种采用2021年可用的3种疫苗产品的汇总接种策略。
  • 模型参数使用美国流行病学、临床和成本数据,分析采用医疗保健和社会视角。

主要发现

  • 社会视角下,与不接种相比,所有成人年龄和风险组接种均节省成本并增加QALY。
  • 医疗保健视角下,18-39岁组需要净投入,ICER范围为8400至15000美元/QALY。
  • 评估疫苗激励计划的场景大多ICER低于100000美元/QALY,但500美元工人奖金场景ICER为22000至134000美元/QALY。
  • 不确定性分析中,结果对疫苗接种成本(疫苗剂量成本、接种管理成本、交通和接种时间成本)最敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Substantial investments by government programs and private health plans subsidized the costs of COVID-19 vaccine doses and vaccine administration. The objective of this study was to evaluate the cost-effectiveness of vaccination against COVID-19 illness during the initial year of COVID-19 vaccination (2021). METHODS: Using a simulation model, we projected outcomes for hypothetical cohorts of US adults aged 18 and older, stratified by age and risk status for complications, comparing vaccination and no vaccination in the context of recommended concomitant prevention strategies (e.g., masking, social distancing). Vaccination against COVID-19 illness and complications used a pooled vaccination strategy for the 3 products available in 2021. Primary outcome measures included incremental cost-effectiveness ratio (ICER), projected costs, and projected quality-adjusted life years (QALYs). The model was parameterized using US epidemiologic, clinical, and cost data and the analysis used the healthcare and societal perspectives. RESULTS: For vaccination against COVID-19 illness compared with no vaccination, vaccination yielded cost savings and QALY gains for all adult age and risk groups using the societal perspective. Using a healthcare sector perspective, ages 18-39 years required a net investment with ICERs ranging from $8400 to $15,000/QALY. Scenarios evaluating vaccine incentive programs mostly yielded ICERs <$100,000/QALY except for worker bonuses of $500 which yielded ICERs of $22,000 to $134,000/QALY. Results were most sensitive to costs of vaccination (dose cost, administration cost, travel and vaccination time costs) across uncertainty analyses. CONCLUSION: Investment in the 2021 vaccination program was attractive from an economic perspective even when using a very conservative approach to the analysis. Future vaccination programs in the US, with different associated cost structures, should be assessed to ensure ongoing value for COVID-19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Prosser LA, Perroud J, Chung GS, et al. The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination. Vaccine. 2025. PMID: 39842151. doi:10.1016/j.vaccine.2025.126725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。